Thu, Dec 18, 2014, 3:56 AM EST - U.S. Markets open in 5 hrs 34 mins

Recent

% | $
Quotes you view appear here for quick access.

CR Bard Inc. Message Board

  • Burry3 Burry3 May 4, 1999 1:47 PM Flag

    Check out CMED who beat earnings

    yesterday by 20%, for the quarter.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Tuesday June 22, 8:42 am Eastern
      Time

      Company Press Release

      Nymox Announces Breakthrough
      Development in Alzheimer Testing

      KENSINGTON,
      Md.--(BUSINESS WIRE)--June 22, 1999-- Nymox Pharmaceutical
      Corporation (NASDAQ National Market: NYMX; Montreal Exchange:
      NMX) announced today that it has developed a
      dramatically improved new urine test for Alzheimer's disease
      (``AD''). The new Nymox ``7C Gold'' test is in a format
      that can easily be packaged for global mass
      distribution.

      The new patented ``7C Gold'' test uses
      special gold particles in a liquid phase system. The test
      will be manufactured in a format that requires no
      special expertise to execute and that will provide rapid
      results that are easy to read. The test has been designed
      for widespread use, in the doctor's office or in the
      clinical lab setting. The Company has not yet announced
      projected dates for introduction of the new test to the
      market, but it is expected to be available for sale in
      many parts of the world in 1999.

      The new
      technological breakthrough is the outcome of a strategic
      collaboration in 1999 between Nymox's new head office assay
      development team led by Dr. Paul Averback and Dr. Colin Bier,
      and an expert team from Serex Inc. (Maywood, New
      Jersey), led by Dr. Judith Fitzpatrick. The new technology
      utilizes materials licensed by Nymox from Harvard
      University, The Massachusetts General Hospital and the
      Research Center at Rhode Island Hospital and Brown
      University School of Medicine, and is based on the
      fundamental research discoveries and worldwide patents
      licensed to Nymox from the prestigious laboratories of Dr.
      Jack Wands and Dr. Suzanne de la Monte.

      Dr.
      Averback said, ``This dramatic breakthrough development
      has the potential to fundamentally change the
      clinical testing of mental function in the world's elderly
      population. For the first time ever, there will be a
      user-friendly, highly accurate, cost-effective and non-invasive
      tool which will be available for manufacture and
      world-wide utilization.''

      The test measures the
      amount of neural thread protein (AD7C-NTP) in the urine.
      This protein is increased in the brain in AD and can
      be measured when it appears in bodily fluids of
      persons with the disease. Multiple independent
      double-blind clinical trials conducted at top institutions in
      the U.S. and published in peer-reviewed journals (see
      The Journal of Clinical Investigation vol. 100, 12
      Dec 1997, 3093-3104; The Journal of Neuropathology
      and Experimental Neurology vol. 55, 10, October 1996,
      1038-1050; The Journal of Clinical Laboratory Analysis vol.
      12, September 1998, 223-226; and vol. 12, 285-288;
      The Journal of Contemporary Neurology 4A, June 1998,
      1-6.) have previously established that AD7C is an
      accurate and specific measurement for AD. Nymox has
      recruited an advisory board of 40 of the top neurologists,
      psychiatrists, neuroscientists, and laboratory medicine
      specialists in North America, who are experts in AD, and who
      currently serve as spokespersons and have widely attested
      to the value of the test product.

      Michael
      Munzar, MD, Medical Director of Nymox, said, ``We believe
      that 7C is the only non-invasive test . . ."

      :)

    • Related QuotesNYMX
      0
      +0
      delayed 20 mins
      - disclaimer
      Tuesday June 22, 8:42 am Eastern
      Time

      Company Press Release

      Nymox Announces Breakthrough
      Development in Alzheimer Testing

      KENSINGTON,
      Md.--(BUSINESS WIRE)--June 22, 1999-- Nymox Pharmaceutical
      Corporation (NASDAQ National Market: NYMX; Montreal Exchange:
      NMX) announced today that it has developed a
      dramatically improved new urine test for Alzheimer's disease
      (``AD''). The new Nymox ``7C Gold'' test is in a format
      that can easily be packaged for global mass
      distribution.

      The new patented ``7C Gold'' test uses
      special gold particles in a liquid phase system. The test
      will be manufactured in a format that requires no
      special expertise to execute and that will provide rapid
      results that are easy to read. The test has been designed
      for widespread use, in the doctor's office or in the
      clinical lab setting. The Company has not yet announced
      projected dates for introduction of the new test to the
      market, but it is expected to be available for sale in
      many parts of the world in 1999.

      The new
      technological breakthrough is the outcome of a strategic
      collaboration in 1999 between Nymox's new head office assay
      development team led by Dr. Paul Averback and Dr. Colin Bier,
      and an expert team from Serex Inc. (Maywood, New
      Jersey), led by Dr. Judith Fitzpatrick. The new technology
      utilizes materials licensed by Nymox from Harvard
      University, The Massachusetts General Hospital and the
      Research Center at Rhode Island Hospital and Brown
      University School of Medicine, and is based on the
      fundamental research discoveries and worldwide patents
      licensed to Nymox from the prestigious laboratories of Dr.
      Jack Wands and Dr. Suzanne de la Monte.

      Dr.
      Averback said, ``This dramatic breakthrough development
      has the potential to fundamentally change the
      clinical testing of mental function in the world's elderly
      population. For the first time ever, there will be a
      user-friendly, highly accurate, cost-effective and non-invasive
      tool which will be available for manufacture and
      world-wide utilization.''

      The test measures the
      amount of neural thread protein (AD7C-NTP) in the urine.
      This protein is increased in the brain in AD and can
      be measured when it appears in bodily fluids of
      persons with the disease. Multiple independent
      double-blind clinical trials conducted at top institutions in
      the U.S. and published in peer-reviewed journals (see
      The Journal of Clinical Investigation vol. 100, 12
      Dec 1997, 3093-3104; The Journal of Neuropathology
      and Experimental Neurology vol. 55, 10, October 1996,
      1038-1050; The Journal of Clinical Laboratory Analysis vol.
      12, September 1998, 223-226; and vol. 12, 285-288;
      The Journal of Contemporary Neurology 4A, June 1998,
      1-6.) have previously established that AD7C is an
      accurate and specific measurement for AD. Nymox has
      recruited an advisory board of 40 of the top neurologists,
      psychiatrists, neuroscientists, and laboratory medicine
      specialists in North America, who are experts in AD, and who
      currently serve as spokespersons and have widely attested
      to the value of the test product.

      Michael
      Munzar, MD, Medical Director of Nymox, said, ``We believe
      that 7C is the only non-invasive test . . ."

    • I have heard that his time with USCI ended when
      it was discovered that he had another job while
      working for USCI. Perhaps he was so bright, one job was
      not challenging enough, although not bright enough to
      keep it hidden. This probably was the best thing that
      ever happened to him. It matters not now of course. He
      did a wonderful sales job with AVE and dumped it off
      to Medtronic in a timely manner. His timing was
      right on that one and he deserves credit. USCI had a
      huge turnover rate, about 33% per year for the sales
      force. This was during the FDA penalty phase. The real
      tragedy is that Bard had no products developed and ready
      to sell when the penalty phase was over! Someone
      really killed that company but it was a great place to
      learn how not to do things.

    • I believe he worked in R&D at USCI eartly on...

    • being an incubator for technical talent. Could you provide some examples?

      Thanks.

    • I have known Bard over 40 years as a supplier and
      later as a part of their organization. Much of what you
      say is exactly right. There were a lot of
      self-serving primadonna, especially in the past 20 years.
      Experienced advice was not often listeened to if it
      conflicted with the "Goals" of upper management. I was a
      principal player in several of the expansions and lived to
      see talent and assets frittered away. There must be a
      near complete turn around in top level thinking and
      attitude if they are to again experience the double digit
      growth that made them exciting in the past. I agree,
      except for the R&D there has been little light at the
      end of what is becoming an exceptionally long tunnel.
      My presesent holdings are only a fraction of what I
      had. I am waiting for more favorable capital gains
      legislation before I liquidate entirely and reinvest in
      positive growth.

    • for top talent in the technology realm.
      Unfortunately, there has been a great diaspora of this talent
      (through layoffs, attrition, and plain ol' piss-poor
      strategic execution) to companies across the industry, many
      of which continue to pummel BCR - this is analogous
      to cutting off your arm and whacking yourself on the
      head with it...

    • However, I think you have the wrong board...

 
BCR
168.87+3.03(+1.83%)Dec 17 4:04 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.